Latest Financials News

Dimerix Limited reported a 22% reduction in its FY2025 loss to $13.25 million, driven by strong licensing revenues and advancing its pivotal Phase 3 clinical trial for DMX-200. The company secured new global partnerships valued at up to AU$1.4 billion, bolstering its cash reserves and commercial prospects.

Lynas Rare Earths reported a 20% revenue increase in FY25 driven by higher NdPr sales, yet net profit fell sharply amid ramp-up costs and market challenges. The company completed key growth projects and unveiled its Towards 2030 strategy focused on downstream expansion.

Perpetual Limited reported a resilient FY25 with a slight dip in underlying profit, offset by strong asset growth and progress on its Simplification Program and Wealth Management sale.

Beamtree Holdings delivered a standout Q4 FY25 with a 12% jump in annual recurring revenue and a 48% surge in operating profit, setting a strong foundation for FY26 growth despite upcoming CFO transition.

Perpetual Limited has announced an ordinary unfranked dividend of AUD 0.54 per share for the half-year ending June 2025, accompanied by a Dividend Reinvestment Plan offering shareholders a choice to reinvest without discount.

BetMakers Technology Group has completed a major transformation in FY25, delivering positive adjusted EBITDA and strong operating cash flow while expanding its global footprint with a strategic US acquisition.

Perpetual Limited reported a modest 2% revenue increase for FY25, yet its net profit after tax plunged by 88%, prompting a cautious outlook despite a declared final dividend.

Lifestyle Communities reported a significant statutory loss for FY25, driven by legal provisions and asset write-downs, yet signs of recovery emerged in the second half with improved sales and cash flow.

BetMakers Technology Group delivered a strong FY25 with a 5.6% half-on-half revenue growth and record profitability, while advancing its technology transformation and signing a strategic acquisition in Nevada.

Telix Pharmaceuticals has received a Complete Response Letter from the FDA for its TLX250-CDx diagnostic agent, citing manufacturing concerns. The company plans immediate remediation and maintains its 2025 revenue guidance.

Emyria Limited reports a reduced net loss of $3.14 million for FY2025, driven by strategic expansion in psychedelic-assisted mental health treatments and key partnerships including insurer Medibank. The company advances clinical services while continuing R&D on proprietary medicines.

DroneShield was not selected as the Systems Integration Partner for the Australian Defence’s LAND 156 program, yet it reported record half-year revenue and profit driven by strong global demand for its counterdrone technology.